Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge.
Antisense oligonucleotide (AO)-mediated exon skipping is a promising new therapy for Duchenne muscular dystrophy (DMD), recently demonstrating proof of principle for restoring the absent dystrophin protein in DMD patients. However, the range of AO chemistries available for exon skipping is limited;...
| Autor principal: | |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado em: |
2010
|